Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can only modulate the final one! @RheumNow #ACR22 Abstr#0955 https://t.co/Vob1GeMN25 https://t.co/CsVshIzp8a

de Hooge & al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA: Radiographic SI according to mNY = 30x higher risk If Rx SI + CRP>6 = 100% risk devlpmt syndesmophytes @ 2 yrs. https://t.co/CR0LymrQdr Abs#1014 #ACR22 @Rheumnow #ACRBest https://t.co/TLWYCJ0eYi

Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inhibitor reintroduction and occur following treatment. @RheumNow #ACR22 Abstr#0758 https://t.co/KCzdJvD0da https://t.co/WQ4eB2hz1k

Giblo et al, 1000+ pop-based cohort RA: Cumulative incidence of depression = Increase in cumulative incidence of anxiety 2005–14 vs. earlier decades Despite improvements in RA ttmts. Maybe time we address these separately? https://t.co/Z3FUgSETKW Abs#0889 #ACR22 @Rheumnow https://t.co/Rn2ru80021

Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of incident PMR in women (HR 1.46). Every 10 pack-years associated 9% increase in risk @RheumNow #ACR22 Abstr#0698 https://t.co/t51fKFs7iJ https://t.co/IS9XC9DXl8

Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a https://t.co/kpXZbRSoMo

DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC BL: 72% obese, 42% dyslipidemia, 38% HBP, MetS 47% Looking forward to seeing the results of this dietary intervention, MetS is high in PsA! https://t.co/29Aq0TLANO Abs#1007 #ACR22 @Rheumnow https://t.co/MoVYnQV6xR

Ab0411 #ACR22 Bimekizumab in AS P3 24 wk PBO control study BE-MOBILE 2 221 BKZ, 111 PBO Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001 Efficacy in both TNF naive and TNF failure pts Wk 24: 1/2 pts has ASDAS<2.1 Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%) @Rheumnow https://t.co/R1ieW0FB6m

Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV

CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls. JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease. PsA > erosions, no diff in other parameters: lack of power or true absence of diff? https://t.co/CR0LymrinT Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx

Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ

I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI